DC Field | Value | Language |
dc.contributor | 臺大醫院-內科部; | en |
dc.contributor.author | Kim, Ho-Youn | en |
dc.contributor.author | Hsu, Ping-Ning | en |
dc.contributor.author | Barba, Merle | en |
dc.contributor.author | Sulaiman, Wahinnuddin | en |
dc.contributor.author | Robertson, Debbie | en |
dc.contributor.author | Vlahos, Bonnie | en |
dc.contributor.author | Khandker, Rezaul | en |
dc.contributor.author | Nab, Henk | en |
dc.contributor.author | Freundlich, Bruce | en |
dc.contributor.author | Koenig, Andrew | en |
dc.creator | Kim, Ho-Youn;Hsu, Ping-Ning;Barba, Merle;Sulaiman, Wahinnuddin;Robertson, Debbie;Vlahos, Bonnie;Khandker, Rezaul;Nab, Henk;Freundlich, Bruce;Koenig, Andrew | en |
dc.creator | 許秉寧 | zh-tw |
dc.date | 2012 | en |
dc.date.accessioned | 2014-02-14T03:35:18Z | - |
dc.date.accessioned | 2018-07-11T06:32:43Z | - |
dc.date.available | 2014-02-14T03:35:18Z | - |
dc.date.available | 2018-07-11T06:32:43Z | - |
dc.date.issued | 2012 | - |
dc.identifier.uri | http://ntur.lib.ntu.edu.tw//handle/246246/258791 | - |
dc.description.abstract | Aim: Rheumatoid arthritis (RA) is an important rheumatologic disease in Asia-Pacific countries, as in other parts of the world. However, limited information is available regarding RA therapy in this region. The Asia-Pacific Study in Patients to be Treated With Etanercept or an Alternative Listed DMARD (APPEAL) compared efficacy and safety of etanercept (ETN) + methotrexate (MTX) versus usual disease-modifying anti-rheumatic drugs (DMARDs) + MTX (reflecting regional practice) in subjects with moderate to severe RA from multiple Asia-Pacific countries.
Method: In this open-label, active-comparator, parallel-design, multicenter study, subjects (n = 300) in the Asia-Pacific region were randomized to ETN + MTX (n = 197) or DMARD + MTX (n = 103). The primary efficacy endpoint was the American College of Rheumatology (ACR) response (ACR-N) area under the curve (AUC) over 16 weeks.
Results: Baseline characteristics were similar between groups. At Week 16, ACR-N AUC indicated a significantly greater response with ETN + MTX compared with DMARD + MTX (mean difference -145.3; P < 0.001). Significantly greater proportions of subjects achieved ACR 20, 50 and 70 responses with ETN + MTX versus DMARD + MTX at Week 16 (P < 0.05). Low Disease Activity Score based on a 28-joint count (DAS28 < 3.2) was also achieved by significantly more subjects in the ETN + MTX group versus the DMARD + MTX group (P < 0.001). Greater improvements were shown for DAS28, pain visual analogue scale, health assessment questionnaire, and physician and patient global assessments (P < 0.05) for ETN + MTX versus DMARD + MTX. No new safety signals were found.
Conclusion: In this Asia-Pacific population of subjects with moderate to severe RA, ETN + MTX showed superior efficacy versus usual DMARD + MTX regimens, with similar safety profiles. | en |
dc.format.extent | 114 bytes | - |
dc.format.mimetype | text/html | - |
dc.language | en-us | en |
dc.relation | Int. J. Rheum. Dis., 15(2), 188-196 | en |
dc.relation.ispartof | Int. J. Rheum. Dis. | - |
dc.subject | Asia-Pacific | en |
dc.subject | efficacy | en |
dc.subject | etanercept | en |
dc.subject | rheumatoid arthritis | en |
dc.subject | safety | en |
dc.title | Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial | en |
dc.relation.pages | 188-196 | - |
dc.relation.journalvolume | 15 | - |
dc.relation.journalissue | 2 | - |
dc.identifier.uri.fulltext | http://ntur.lib.ntu.edu.tw/bitstream/246246/258791/1/index.html | - |
item.grantfulltext | open | - |
item.fulltext | with fulltext | - |
Appears in Collections: | 醫學系
|